Axicabtagene ciloleucel compared to standard of care in Canadian patients with relapsed or refractory large B-cell lymphoma: a cost-effectiveness analysis of the ZUMA-7 trial
Treatment with axi-cel in 2L is a cost-effective option that addresses an important unmet clinical need for Canadian patients with r/r LBCL.
Authors
- Heather Cameron (ORCID: https://orcid.org/0000-0002-3886-8257)
- Laurie H. Sehn (ORCID: https://orcid.org/0000-0003-1860-9765)
- Susan L. Whitney (ORCID: https://orcid.org/0000-0003-4271-8718)
- John Kuruvilla (ORCID: https://orcid.org/0000-0002-6117-320X)
- Anik R. Patel (ORCID: https://orcid.org/0000-0001-9091-8904)
- Geoffrey Reid
Institutions
- University of British Columbia (CA)
- Spinal Cord Injury BC (CA)
- Princess Margaret Cancer Centre (CA)
- EVERSANA (Canada) (CA)
- Gilead Sciences (France) (FR)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2025-05-02
- DOI
- https://doi.org/10.1080/13696998.2025.2498853
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00